Hangzhou Sciwind Biosciences Co Ltd, a clinical-stage biopharmaceutical company, announced on Sunday that it has named Dr Weidong Zhong as the new chief strategy officer and president of its US subsidiary, Sciwind Biosciences USA.

Dr Zhong was the co-founder, CEO and chief scientific officer of Terns Pharmaceuticals. He was the global head of Antiviral Research at Novartis and senior director of Biology at Gilead Sciences. He has also held research leadership positions at Valeant Pharmaceuticals, Schering-Plough Research Institute and SmithKline Beecham.

Hai Pan, PhD, founder and CEO of Sciwind, said, 'Dr Zhong is a highly accomplished industry leader with an extensive track record in discovering and developing innovative therapies to treat infectious and metabolic diseases. His knowledge and expertise will be very valuable to Sciwind as we advance our differentiated product pipeline through development in China as well as in other global markets. We are thrilled to have Dr Zhong join us at this critical time in our company's growth history and lead our development activities for the global markets.'